Mutation Position Within Evolutionary Subclonal Architecture in AML

Seminars in Hematology

Volumn 51, Issue 4, 2014, Pages 273-281

  Welch, John S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; QUIZARTINIB; RETINOIC ACID; SORAFENIB; SUNITINIB; WT1 PROTEIN; NUCLEOTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER RISK; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CLONE; DNMT3A GENE; FLT3 GENE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; KIT GENE; LEUKEMIA RELAPSE; MOLECULAR EVOLUTION; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; SUBCLONE; TET2 GENE; WT1 GENE; BIOLOGICAL MODEL; GENETICS; MUTATION;

HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, GENETIC; MUTATION; NUCLEOTIDES;

EID: 84907997640     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.08.004     Document Type: Article

References (91)

1. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
2. Testa J.R., Mintz U., Rowley J.D., Vardiman J.W., Golomb H.M. Evolution of karyotypes in acute nonlymphocytic leukemia. Cancer Res 1979, 39:3619-3627.
3. Estey E., Keating M.J., Pierce S., Stass S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 1995, 9:972-976.
4. Garson O.M., Hagemeijer A., Sakurai M., et al. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. Cancer Genet Cytogenet 1989, 40:187-202.
5. Kern W., Haferlach T., Schnittger S., et al. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. Leukemia 2002, 16:2084-2091.
6. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
7. Stark B., Jeison M., Gobuzov R., et al. Apparently unrelated clones shown by spectral karyotyping to represent clonal evolution of cryptic t(10;11)(p13;q23) in a patient with acute monoblastic leukemia. Cancer Genet Cytogenet 2000, 120:105-110.
8. Anderson K., Lutz C., van Delft F.W., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
9. Schmetzer H.M., Gerhartz H.H. Acute myeloid leukemia (AML) can be oligoclonal. Leukemia 1993, 7:1965-1970.
10. Gale R.E. Evaluation of clonality in myeloid stem-cell disorders. Semin Hematol 1999, 36:361-372.
11. Lo Coco F., Saglio G. Single or multistep origin of hemopoietic tumors: the contribution of clonality studies. Leukemia 1995, 9:1586-1589.
12. Welch J.S., Ley T.J., Link D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:1-15.
13. Jan M., Snyder T.M., Corces-Zimmerman M.R., et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012, 4:149ra118.
14. Welch J.S. Subclonal architecture in acute myeloid leukemia. In: Hematology Education 2013, 23-29. European Hematology Association, Stockholm, Sweden.
15. Kern W., Haferlach C., Haferlach T., Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 2008, 112:4-16.
16. Larson R.A., Kondo K., Vardiman J.W., et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984, 76:827-841.
17. Schnittger S., Alpermann T., Nadarajah N., et al. Comparison of mutation patterns between diagnosis and relapse in 444 patients with acute myeloid leukemia shows high variability of stability and influence on time to relapse. American Society of Hematology 2012, December 8-11, (Atlanta, Ga).
18. Tsukamoto N., Karasawa M., Tanaka Y., et al. Recurrence of acute myelogenous leukemia with the same AML1/ETO breakpoint as at diagnosis after complete remission lasting 15 years: analysis of stored bone marrow smears. Int J Hematol 2003, 78:362-369.
19. De Botton S., Chevret S., Sanz M., et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 Trial. Br J Haematol 2000, 111:801-806.
20. Schoch C., Haase D., Haferlach T., et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol 1996, 94:493-500.
21. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children[U+05F3]s Leukaemia Working Parties. Blood 1998, 92:2322-2333.
22. Berger R., Le Coniat M., Derre J., et al. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities. Genes Chromosomes Cancer 1991, 3:332-337.
23. Wan T.S., Ma S.K., Au W.Y., et al. Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia. Cancer Genet Cytogenet 2003, 140:170-173.
24. Sessarego M., Fugazza G., Balleari E., et al. High frequency of trisomy 8 in acute promyelocytic leukemia: a fluorescence in situ hybridization study. Cancer Genet Cytogenet 1997, 97:161-164.
25. Pantic M., Novak A., Marisavljevic D., et al. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Med Oncol 2000, 17:307-313.
26. Kwong Y.L., Wong K.F., Chan T.K. Trisomy 8 in acute promyelocytic leukaemia: an interphase study by fluorescence in situ hybridization. Br J Haematol 1995, 90:697-700.
27. Hiorns L.R., Swansbury G.J., Mehta J., et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997, 96:314-321.
28. Paschka P., Du J., Schlenk R.F., et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 2013, 121:170-177.
29. Jones D., Yao H., Romans A., et al. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer 2010, 49:182-191.
30. Wakita S., Yamaguchi H., Miyake K., et al. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 2010, 25:1423-1432.
31. Allen C., Hills R.K., Lamb K., et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 2013, 27:1891-1901.
32. Olshanskaya Y.V., Gutorova D.S., Shuravina E.N., et al. The incidence and prognostic significance of additional chromosome restructuring in acute promyelocytic leukemia. Gematologiya I Transfuziologiya 2007, 52:27-32.
33. Slack J.L., Arthur D.C., Lawrence D., et al. Secondary cytogenetic changes in acute promyelocytic leukemia-prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol 1997, 15:1786-1795.
34. Hernandez J.M., Martin G., Gutierrez N.C., et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica 2001, 86:807-813.
35. Lin P., Chen L., Luthra R., et al. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol 2008, 21:1029-1036.
36. Peniket A., Wainscoat J., Side L., et al. Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol 2005, 129:210-220.
37. Bacher U., Haferlach T., Alpermann T., et al. Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. Br J Haematol 2011, 152:713-720.
38. Hayashi Y., Raimondi S.C., Behm F.G., et al. Two karyotypically independent leukemic clones with the t(8;21) and 11q23 translocation in acute myeloblastic leukemia at relapse. Blood 1989, 73:1650-1655.
39. Kadam P.S., Jain H.V., Parikh P.M., et al. Emergence of an unrelated highly aberrant clone in an AML patient at relapse four months after peripheral blood stem cell transplantation. Indian J Hum Genet 2007, 13:114-118.
40. Potter N.E., Ermini L., Papaemmanuil E., et al. Composite single cell genetics and clonal phylogeny in acute lymphoblastic leukaemia. American Society of Hematology 2012, (Atlanta, Ga).
41. Nakano Y., Kiyoi H., Miyawaki S., et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 1999, 104:659-664.
42. Klco J.M., Spencer D.H., Miller C.A., et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014, 25:379-392.
43. Shlush L.I., Zandi S., Mitchell A., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506:328-333.
44. Schnittger S., Bacher U., Haferlach C., et al. Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer 2012, 51:910-924.
45. Beierl K., Tseng L.H., Beierl R., et al. Detection of minor clones with internal tandem duplication mutations of FLT3 gene in acute myeloid leukemia using delta-PCR. Diagn Mol Pathol 2013, 22:1-9.
46. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
47. Singh R.R., Bains A., Patel K.P., et al. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn 2012, 14:336-345.
48. Bisling K.E., Brewin J.N., McGovern A.P., et al. DNMT3A mutations at R882 hotspot are only found in major clones of acute myeloid leukemia. Leuk Lymphoma 2014, 55:711-714.
49. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074. Cancer Genome Atlas Research N.
50. Kristensen T., Moller M.B., Friis L., et al. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. Eur J Haematol 2011, 87:400-408.
51. Boissel N., Renneville A., Biggio V., et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005, 106:3618-3620.
52. Suzuki T., Kiyoi H., Ozeki K., et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005, 106:2854-2861.
53. Bachas C., Schuurhuis G.J., Assaraf Y.G., et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 2012, 26:1313-1320.
54. Tiesmeier J., Muller-Tidow C., Westermann A., et al. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. Leuk Res 2004, 28:1069-1074.
55. Wakita S., Yamaguchi H., Omori I., et al. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia 2012, 27:1044-1052.
56. Hou H.A., Kuo Y.Y., Liu C.Y., et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012, 119:559-568.
57. McCormick S.R., McCormick M.J., Grutkoski P.S., et al. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. Arch Pathol Lab Med 2010, 134:1143-1151.
58. Nazha A., Cortes J., Faderl S., et al. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica 2012, 97:1242-1245.
59. Wang E.S., Sait S.N., Gold D., et al. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Cancer Genet Cytogenet 2010, 202:101-107.
60. Hou H.A., Huang T.C., Lin L.I., et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010, 115:5222-5231.
61. Chou W.C., Lei W.C., Ko B.S., et al. The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011, 25:246-253.
62. Schnittger S., Kern W., Tschulik C., et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009, 114:2220-2231.
63. Dvorakova D., Racil Z., Jeziskova I., et al. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations. Am J Hematol 2010, 85:926-929.
64. Jain P., Kantarjian H., Patel K., et al. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 2014, 55:1337-1344.
65. Bartram C.R., Ludwig W.D., Hiddemann W., et al. Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci. Leukemia 1989, 3:247-256.
66. Kottaridis P.D., Gale R.E., Langabeer S.E., Frew M.E., Bowen D.T., Linch D.C. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002, 100:2393-2398.
67. Nakamura H., Inokuchi K., Yamaguchi H., Dan K. Abnormalities of p51, p53, FLT3 and N-ras genes and their prognostic value in relapsed acute myeloid leukemia. J Nippon Med Sch 2004, 71:270-278.
68. Shih L.Y., Liang D.C., Huang C.F., et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 2008, 22:303-307.
69. Shih L.Y., Liang D.C., Huang C.F., et al. AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples. Leukemia 2006, 20:604-609.
70. Ottone T., Zaza S., Divona M., et al. Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin. Br J Haematol 2013, 161:533-540.
71. Abdelhamid E., Preudhomme C., Helevaut N., et al. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res 2012, 36:316-323.
72. Krönke J., Bullinger L., Teleanu V., et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013, 122:100-108.
73. Cloos J., Goemans B.F., Hess C.J., et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006, 20:1217-1220.
74. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
75. Walter M.J., Shen D., Ding L., et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012, 366:1090-1098.
76. Lin T.L., Nagata Y., Kao H.W., et al. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica 2014, 99:28-36.
77. Corces-Zimmerman M.R., Hong W.J., Weissman I.L., Medeiros B.C., Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014, 111:2548-2553.
78. Busque L., Mio R., Mattioli J., et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 1996, 88:59-65.
79. Gale R.E., Fielding A.K., Harrison C.N., Linch D.C. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol 1997, 98:512-519.
80. Laurie C.C., Laurie C.A., Rice K., et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 2012, 44:642-650.
81. Busque L., Patel J.P., Figueroa M.E., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012, 44:1179-1181.
82. Price C.M., Marshall C.J., Bashey A. Sequential acquisition of trisomy 8 and N-ras mutation in acute myeloid leukaemia demonstrated by analysis of isolated leukaemic colonies. Br J Haematol 1994, 88:338-342.
83. Shouval R., Shlush L.I., Yehudai-Resheff S., et al. Single cell analysis exposes intra-tumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis. Exp Hematol 2014, 42:457-463.
84. Pratz K.W., Sato T., Murphy K.M., et al. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010, 115:1425-1432.
85. Smith C.C., Wang Q., Chin C.S., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263.
86. Moore A.S., Faisal A., Gonzalez de Castro D., et al. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia 2012, 26:1462-1470.
87. Baker S.D., Zimmerman E.I., Wang Y.D., et al. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res 2013, 19:5758-5768.
88. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
89. Chen W., Jones D., Medeiros L.J., Luthra R., Lin P. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol 2005, 130:726-728.
90. Carnicer M.J., Nomdedeu J.F., Lasa A., et al. FLT3 mutations are associated with other molecular lesions in AML. Leuk Res 2004, 28:19-23.
91. Deschler B., Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006, 107:2099-2107.